Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-4762
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate ; volume:53 ; number:1 ; day:13 ; month:7 ; year:2022 ; pages:1-11 ; date:12.2022
The Egyptian Journal of Radiology and Nuclear Medicine ; 53, Heft 1 (13.7.2022), 1-11, 12.2022
- Urheber
-
Simonsen, Jane A.
Thøgersen, Karin F.
Hvidsten, Svend
Gerke, Oke
Høilund-Carlsen, Poul F.
Diederichsen, Louise P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43055-022-00822-z
- URN
-
urn:nbn:de:101:1-2022091521582315663275
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Simonsen, Jane A.
- Thøgersen, Karin F.
- Hvidsten, Svend
- Gerke, Oke
- Høilund-Carlsen, Poul F.
- Diederichsen, Louise P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD